May 16 (Reuters) - Halozyme Therapeutics Inc:
* Delivers notice of breach to Baxter healthcare due to Hylenex(R)
manufacturing failures
* Says Baxter recently informed it that some materials produced by Baxter are
not in compliance with requirements of hylenex agreements
* Says in the event that Baxter is unable to remedy all material breaches
within 120 days, Halozyme may terminate the hylenex relationship
* Says no medical events have been reported in connection with noncompliant
hylenex product
* Says working with the U.S. food and drug administration and Baxter to ensure
patient safety
* Says Halozyme and Baxter are actively investigating both the causes and the
extent of these manufacturing issues
* Says believes that baxter's manufacturing deficiencies are specific to the
150u hylenex product
* Says neither the rhuph20 bulk enzyme nor any other products containing the
enzyme are believed to be affected
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Halozyme Therapeutics Inc click here:) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Delivers notice of breach to Baxter healthcare due to Hylenex(R)
manufacturing failures
* Says Baxter recently informed it that some materials produced by Baxter are
not in compliance with requirements of hylenex agreements
* Says in the event that Baxter is unable to remedy all material breaches
within 120 days, Halozyme may terminate the hylenex relationship
* Says no medical events have been reported in connection with noncompliant
hylenex product
* Says working with the U.S. food and drug administration and Baxter to ensure
patient safety
* Says Halozyme and Baxter are actively investigating both the causes and the
extent of these manufacturing issues
* Says believes that baxter's manufacturing deficiencies are specific to the
150u hylenex product
* Says neither the rhuph20 bulk enzyme nor any other products containing the
enzyme are believed to be affected
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Halozyme Therapeutics Inc click here:) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2010 AFX News
